RU2015101081A - Стабилизированный gp120 - Google Patents
Стабилизированный gp120 Download PDFInfo
- Publication number
- RU2015101081A RU2015101081A RU2015101081A RU2015101081A RU2015101081A RU 2015101081 A RU2015101081 A RU 2015101081A RU 2015101081 A RU2015101081 A RU 2015101081A RU 2015101081 A RU2015101081 A RU 2015101081A RU 2015101081 A RU2015101081 A RU 2015101081A
- Authority
- RU
- Russia
- Prior art keywords
- polypeptide
- seq
- stabilized
- fusion protein
- hiv
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 claims abstract 44
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 44
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 44
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract 8
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims abstract 8
- 239000010410 layer Substances 0.000 claims abstract 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 5
- 235000001014 amino acid Nutrition 0.000 claims abstract 2
- 150000001413 amino acids Chemical class 0.000 claims abstract 2
- 239000011229 interlayer Substances 0.000 claims abstract 2
- 230000002163 immunogen Effects 0.000 claims 13
- 239000012634 fragment Substances 0.000 claims 8
- 108020001507 fusion proteins Proteins 0.000 claims 8
- 102000037865 fusion proteins Human genes 0.000 claims 8
- 239000002157 polynucleotide Substances 0.000 claims 6
- 102000040430 polynucleotide Human genes 0.000 claims 6
- 108091033319 polynucleotide Proteins 0.000 claims 6
- 239000013638 trimer Substances 0.000 claims 5
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261661050P | 2012-06-18 | 2012-06-18 | |
| US61/661,050 | 2012-06-18 | ||
| PCT/EP2013/062553 WO2013189901A1 (en) | 2012-06-18 | 2013-06-17 | Stabilized gp120 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015101081A true RU2015101081A (ru) | 2016-08-10 |
Family
ID=48628698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015101081A RU2015101081A (ru) | 2012-06-18 | 2013-06-17 | Стабилизированный gp120 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20150183835A1 (enExample) |
| EP (1) | EP2861249A1 (enExample) |
| JP (1) | JP2015521592A (enExample) |
| KR (1) | KR20150023735A (enExample) |
| CN (1) | CN104619338A (enExample) |
| AU (1) | AU2013279456A1 (enExample) |
| CA (1) | CA2876762A1 (enExample) |
| IL (1) | IL235898A0 (enExample) |
| IN (1) | IN2014KN02740A (enExample) |
| MX (1) | MX2014014682A (enExample) |
| RU (1) | RU2015101081A (enExample) |
| SG (1) | SG11201407995RA (enExample) |
| WO (1) | WO2013189901A1 (enExample) |
| ZA (1) | ZA201408840B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10400015B2 (en) | 2014-09-04 | 2019-09-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant HIV-1 envelope proteins and their use |
| RU2745373C2 (ru) * | 2014-09-23 | 2021-03-24 | БЁРИНГЕР ИНГЕЛЬХАЙМ ЭНИМАЛ ХЕЛТ ЮЭсЭй ИНК. | Рекомбинантные вакцины от fmdv и их применение |
| US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| US10808011B2 (en) | 2016-03-09 | 2020-10-20 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Recombinant HIV-1 envelope proteins and their use |
| WO2018075989A1 (en) | 2016-10-21 | 2018-04-26 | Altor Bioscience Corporation | Multimeric il-15-based molecules |
| US11136356B2 (en) | 2017-10-16 | 2021-10-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant HIV-1 envelope proteins and their use |
| CN109851664A (zh) * | 2017-11-30 | 2019-06-07 | 清华大学 | 一种基于抗体反向表位设计的蛋白质及其在制备抗艾滋病病毒疫苗中的应用 |
| EP3810755A4 (en) | 2018-06-19 | 2021-12-01 | Nantcell, Inc. | COMPOSITIONS AND METHODS OF TREATMENT FOR HIV |
| WO2021249013A1 (en) * | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Vaccine compositions, methods, and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2786488B1 (fr) * | 1998-11-27 | 2003-04-25 | Orstom | Mutants de la gp120 et leurs applications biologiques |
| EP1198468A4 (en) * | 1999-06-25 | 2003-07-30 | Progenics Pharm Inc | STABILIZED VIRAL ENVELOPE PROTEINS AND THEIR USE |
| BRPI0815743A2 (pt) * | 2007-08-24 | 2015-02-18 | Novartis Ag | Proteínas hiv env com modificações no laço v3 |
| CA2774636C (en) * | 2009-09-25 | 2019-05-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 and their use |
-
2013
- 2013-06-17 IN IN2740KON2014 patent/IN2014KN02740A/en unknown
- 2013-06-17 SG SG11201407995RA patent/SG11201407995RA/en unknown
- 2013-06-17 AU AU2013279456A patent/AU2013279456A1/en not_active Abandoned
- 2013-06-17 JP JP2015516648A patent/JP2015521592A/ja active Pending
- 2013-06-17 RU RU2015101081A patent/RU2015101081A/ru not_active Application Discontinuation
- 2013-06-17 KR KR20157000850A patent/KR20150023735A/ko not_active Withdrawn
- 2013-06-17 CN CN201380032027.2A patent/CN104619338A/zh active Pending
- 2013-06-17 EP EP13729364.3A patent/EP2861249A1/en not_active Withdrawn
- 2013-06-17 WO PCT/EP2013/062553 patent/WO2013189901A1/en not_active Ceased
- 2013-06-17 MX MX2014014682A patent/MX2014014682A/es unknown
- 2013-06-17 US US14/408,466 patent/US20150183835A1/en not_active Abandoned
- 2013-06-17 CA CA2876762A patent/CA2876762A1/en not_active Abandoned
-
2014
- 2014-11-25 IL IL235898A patent/IL235898A0/en unknown
- 2014-12-02 ZA ZA2014/08840A patent/ZA201408840B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL235898A0 (en) | 2015-01-29 |
| WO2013189901A1 (en) | 2013-12-27 |
| ZA201408840B (en) | 2016-08-31 |
| CN104619338A (zh) | 2015-05-13 |
| KR20150023735A (ko) | 2015-03-05 |
| JP2015521592A (ja) | 2015-07-30 |
| US20150183835A1 (en) | 2015-07-02 |
| AU2013279456A1 (en) | 2014-12-18 |
| MX2014014682A (es) | 2015-03-04 |
| SG11201407995RA (en) | 2015-01-29 |
| IN2014KN02740A (enExample) | 2015-05-08 |
| EP2861249A1 (en) | 2015-04-22 |
| CA2876762A1 (en) | 2013-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015101081A (ru) | Стабилизированный gp120 | |
| JP2015521592A5 (enExample) | ||
| MX340015B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340016B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| NZ622048A (en) | Hybrid polypeptides including meningococcal fhbp sequences | |
| JP2013507907A5 (enExample) | ||
| JP2015214545A5 (enExample) | ||
| AR107020A2 (es) | Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9) | |
| HRP20160798T1 (hr) | Rekombinantni antigeni iz rsv | |
| RU2014134365A (ru) | Вакцины против clostridium difficile, включающие рекомбинантные токсины | |
| JP2015529678A5 (enExample) | ||
| SI2340038T1 (en) | A biochemically stabilized HIV-1 ENV TRIMER vaccine | |
| RU2014135053A (ru) | Иммуногены для вакцинации против вич | |
| US8790898B2 (en) | Synthetic peptides corresponding to overlapping neutralizing determinants in the CBD1 epitope induce broadly neutralizing antibodies | |
| RU2015119523A (ru) | Новый способ лечения повреждения спинного мозга с применением фрагмента hmgb1 | |
| RU2019126232A (ru) | Пептиды и способы для лечения диабета | |
| RU2014127714A (ru) | ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile | |
| JP2009520758A5 (enExample) | ||
| JP2012102105A5 (enExample) | ||
| EA201892233A1 (ru) | Композиции и способы, связанные с иммуногенами вич-1 | |
| WO2012047267A3 (en) | Polyvalent immunogen | |
| JP2016520534A5 (enExample) | ||
| PH12013501728A1 (en) | Combined cell based gp96-ig-siv/hiv, recombinant gp120 protein vaccination for protection from siv/hiv | |
| EA201591108A1 (ru) | Слитый гормон роста человека и альбумин, составы и их применения | |
| RU2020106669A (ru) | Синтетические белки и пути их терапевтического применения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20170726 |